Similar Incidence of Typhlitis in Patients Receiving Various Doses of Daunorubicin or Idarubicin As Induction for Acute Myeloid Leukemia

被引：0
|
作者：
Seddon, Amanda N. [1 ]
Michael, Angela G. [2 ]
Adel, Nelly G. [2 ]
Tallman, Martin S. [2 ]
Akin, Oguz [2 ]
Chaim, Joshua [2 ]
Drill, Esther [2 ]
机构：
[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Idarubicin Versus Daunorubicin Versus Mitoxantrone for Induction Chemotherapy in Acute Myeloid Leukemia: Patient Registration Study of Turkish Society of HematologyAcute Myeloid Leukemia Working Group
    Pinar, Ibrahim Ethem
    Celik, Serhat
    Polat, Merve Gokcen
    Karatas, Aylin Fatma
    Dogan, Ali
    Iltar, Utku
    Seval, Guldane Cengiz
    Malkan, Umit Yavuz
    Ince, Idris
    Yenihayat, Emel Merve
    Akdeniz, Aydan
    Kacmaz, Murat
    Erdem, Ramazan
    Ozturk, Hacer Berna Afacan
    Kirkizlar, Hakki Onur
    Akat, Gulten Korkmaz
    Aykas, Fatma
    Mehtap, Ozgur
    Deveci, Burak
    Sevindik, Omur Gokmen
    BLOOD, 2023, 142
  • [22] Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia
    Zhang, Qi
    Zhang, Chun-Hong
    Wang, Zhen-Dong
    Wang, Dong
    TUMORI JOURNAL, 2022, 108 (02): : 182 - 188
  • [23] Daunorubicin versus mitoxantrone for induction therapy of patients of de novo acute myeloid leukemia
    Varadpande, L.
    Rajappa, S.
    Naidu, N.
    Digumarti, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Induction of acute myeloid leukemia (AML) with idarubicin, cytarabine and cladribine (ICC).
    Wiedower, Eric
    Jamy, Omer Hassan
    Martin, Michael Gary
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] IDARUBICIN OVERCOMES MULTIDRUG RESISTANT 1 INDUCED CHEMORESISTANCE WITH HIGHER INDUCTION REMISSION RATE THAN DAUNORUBICIN IN de NOVO ACUTE MYELOID LEUKEMIA PATIENTS
    Xu, B.
    Zha, Z.
    Chen, F.
    Shi, P.
    Guo, X.
    Fan, F.
    Huang, H.
    HAEMATOLOGICA, 2012, 97 : 26 - 26
  • [26] Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia
    Berman, E
    Wiernik, P
    Vogler, R
    VelezGarcia, E
    Bartolucci, A
    Whaley, FS
    CANCER, 1997, 80 (11) : 2181 - 2185
  • [27] Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90
    Begna, Kebede H.
    Gangat, Naseema
    Shah, Mithun V.
    Alkhateeb, Hassan B.
    Patnaik, Mrinal M.
    Al-Kali, Aref
    Elliot, Michelle A.
    Hogan, William J.
    Litzow, Mark R.
    Hook, C. Christopher
    Mangaonkar, Abhishek A.
    Viswanatha, David S.
    Chen, Dong
    Pardanani, Animesh D.
    Ketterling, Rhett P.
    Tefferi, Ayalew
    BLOOD, 2021, 138
  • [28] Incidence of CDI and Association with Antibiotics in a Cohort of Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Induction Chemotherapy
    Jakob, Carolin
    Bauquet, Aurelie
    Buffet, Renaud
    Vehreschild, Maria
    Vehreschild, Janne
    BLOOD, 2020, 136
  • [29] What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?
    Priyanka Pophali
    Mark Litzow
    Current Treatment Options in Oncology, 2017, 18
  • [30] What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?
    Pophali, Priyanka
    Litzow, Mark
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
12345